IFNG and hemophagocytic syndrome: Both patients achieved rapid liver function recovery following a targeted regimen combining chemotherapy and emapalumab, a human anti-IFN-γ monoclonal antibody approved for primary HLH.<h4>Conclusion</h4>The GSD index emerges as a robust prognostic tool for NK/T-HLH patients with hepatic dysfunction, reflecting underlying IFN-γ-mediated immunopathology.